Egrifta (Tesamorelin) in Children Under 12: Off-Label Use, Evidence, and Clinical Guidance

What Tesamorelin Is and Why Its FDA Label Excludes Children

Tesamorelin is a synthetic analog of endogenous growth-hormone-releasing hormone (GHRH). The FDA approved it in November 2010 under the brand name Egrifta specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. [1] The approval was based on two phase 3 randomized controlled trials (TRIAL F2301, N=412, and TRIAL F2302, N=357) that enrolled adults only. [2] Children under 12 were explicitly excluded from those trials.

The label sets no pediatric dosing parameters for any age group. FDA-approved prescribing information states that safety and efficacy in pediatric patients have not been established. [1]

Why the Exclusion Matters Biologically

Children under 12 have open epiphyseal growth plates. Supraphysiologic stimulation of the GH/IGF-1 axis during this window carries theoretical risk of accelerated bone maturation, which could paradoxically reduce final adult height. The same concern has shaped cautious labeling for recombinant human GH (rhGH) products such as somatropin, where pediatric dosing is weight-based and tightly monitored. [3]

Endogenous GHRH pulses in prepubertal children already drive GH secretion at higher pulse amplitude than in adults. Adding an exogenous GHRH analog on top of that baseline could push IGF-1 well above age-adjusted normal ranges. Elevated IGF-1 in children has been associated with increased cancer risk in epidemiologic studies, including a 2004 meta-analysis in The Lancet that found higher circulating IGF-1 linked to colorectal, breast, and prostate cancers. [4]

The Pediatric Research Equity Act and Why No Trial Exists

The Pediatric Research Equity Act (PREA) authorizes the FDA to require pediatric studies for drugs that may be used in children. [5] The FDA has not issued a Written Request or Required Assessment for tesamorelin in children, reflecting the agency's judgment that HIV-associated lipodystrophy in the under-12 population is not a sufficiently prevalent or clinically established indication to mandate trials. Without a mandated trial, pharmaceutical sponsors have not generated the data needed for a pediatric label. [5]

Pharmacology in a Developing Pituitary: What the Science Suggests

Tesamorelin binds GHRH receptors on anterior pituitary somatotrophs. In healthy adults, a single 2 mg subcutaneous dose raises mean GH area under the curve (AUC) roughly 10-fold above baseline within 30 minutes. [6] In children, the pituitary somatotroph population is larger relative to body mass, and GHRH receptor density is higher, meaning the same weight-based dose could produce a proportionally larger GH spike. [7]

IGF-1 Physiology in Children Under 12

IGF-1 acts as the primary downstream mediator of GH. Normal IGF-1 reference ranges in prepubertal children (ages 2 to 11) run from approximately 88 to 452 ng/mL depending on age and Tanner stage. [8] Adult tesamorelin trials showed mean IGF-1 increases of 81 to 114 ng/mL from baseline after 26 weeks of 2 mg daily dosing. [2] Overlaying that increment onto a child already at the upper end of age-adjusted IGF-1 range produces values consistent with acromegaloid excess. Sustained IGF-1 excess in growing bone drives cortical thickening, jaw prognathism, and soft-tissue overgrowth. [9]

Glucose Metabolism Considerations

GH is counter-regulatory to insulin. Tesamorelin in adult HIV-positive patients produced a statistically significant increase in fasting glucose versus placebo in F2301: mean change +5.3 mg/dL (P<0.05). [2] Children under 12 are not immune to GH-induced insulin resistance. Prepubertal children with growth-hormone excess from pituitary adenomas develop impaired fasting glucose at rates higher than age-matched controls. [10] Any off-label pediatric protocol must therefore include fasting glucose and HbA1c monitoring at baseline, 3 months, and 6 months at minimum.

Documented Off-Label Scenarios Where Clinicians Have Considered Tesamorelin in Children

No published randomized trial has tested tesamorelin in patients under 12. A small number of case reports and single-center retrospective analyses have described use in older pediatric patients (ages 12 to 17) with HIV-associated lipodystrophy, but these represent a distinct population from the under-12 group. [11]

HIV-Associated Lipodystrophy in Young Children

HIV-positive children can develop peripheral fat loss and central fat accumulation from antiretroviral therapy (ART), particularly regimens containing protease inhibitors or thymidine analog nucleoside reverse transcriptase inhibitors (NRTIs). A 2016 study in the Journal of Acquired Immune Deficiency Syndromes documented lipodystrophy in 49 of 152 HIV-positive children (32%) aged 2 to 12 years on long-term ART. [12] The metabolic burden is real. However, switching ART regimens or adding diet and exercise interventions remain first-line approaches endorsed by the Pediatric HIV guidelines published through the NIH AIDSinfo platform. [13] Tesamorelin has not been incorporated into those guidelines for any pediatric age group.

Growth Hormone Deficiency: Why Tesamorelin Is Not the Right Tool

Some clinicians have asked whether tesamorelin could substitute for rhGH in children with GH deficiency. The short answer is no. Tesamorelin stimulates endogenous GH secretion and therefore requires an intact pituitary. Children with GH deficiency due to pituitary hypoplasia, craniopharyngioma resection, or radiation damage have impaired somatotroph function, meaning tesamorelin would produce little or no GH response. [14] Recombinant human GH (somatropin) bypasses the pituitary entirely and remains the standard of care for pediatric GH deficiency under Endocrine Society guidelines. [3]

Lipodystrophy from Non-HIV Causes

Familial partial lipodystrophy (FPLD) and acquired generalized lipodystrophy (AGL) can present in early childhood. Published case reports describe the use of metreleptin (a leptin analog) in children with generalized lipodystrophy, and that drug received FDA approval for this indication in 2014. [15] No published case report describes tesamorelin use specifically in a child under 12 with non-HIV lipodystrophy. Tesamorelin's mechanism, reducing visceral fat via GH-mediated lipolysis, is theoretically relevant but completely untested in this population.

Regulatory and Ethical Framework for Any Contemplated Use

Prescribing tesamorelin off-label to a patient under 12 requires navigating several overlapping requirements. The following framework reflects current FDA and institutional standards.

Step 1: Establish That No Approved Alternative Exists

Before considering tesamorelin, the clinician must document that approved alternatives (metreleptin for lipodystrophy, somatropin for GH deficiency, ART switch for HIV lipodystrophy) are either contraindicated, have failed, or are not applicable to the patient's specific diagnosis. The FDA's off-label use guidance states that physicians may prescribe approved drugs for unapproved uses when supported by sound scientific evidence and in patients' best interest, but the burden of documentation falls on the prescriber. [16]

Step 2: Obtain Institutional Review Board (IRB) Oversight or a Compassionate Use IND

Single-patient compassionate use of an unapproved pediatric dosing regimen generally requires an Investigational New Drug (IND) application under 21 CFR Part 312, or enrollment under an existing expanded-access protocol. [17] The FDA processed 1,873 individual patient expanded-access requests in fiscal year 2022, approving 99.5% of emergency requests within 24 hours. [17] Clinicians who believe tesamorelin is necessary for a specific child under 12 should contact the FDA's Office of Oncology Products or the relevant therapeutic division directly.

Step 3: Informed Consent with Explicit Uncertainty Disclosure

Parents or legal guardians must receive written informed consent that explicitly states: no controlled trial data exists for this age group, long-term effects on linear growth and pubertal timing are unknown, and IGF-1 overstimulation could harm growth plate integrity. The American Academy of Pediatrics policy on off-label drug use requires that consent documentation include a plain-language summary of the evidence gap. [18]

Step 4: Mandatory Monitoring Parameters

Any off-label protocol must include at minimum: IGF-1 at baseline and every 3 months, fasting glucose and HbA1c at baseline and every 3 months, left-hand bone-age X-ray at baseline and every 6 months, and Tanner staging at each visit. If IGF-1 exceeds 2.0 standard deviations above the age-adjusted mean, the dose must be reduced or discontinued. This threshold aligns with monitoring standards used in pediatric rhGH trials. [3]

Safety Signals from Adult Trials Extrapolated to Children

Because no pediatric data exist, clinicians must extrapolate from adult phase 3 data with caution. The two key adult trials (F2301 and F2302) reported the following adverse events at rates exceeding placebo by more than 5 percentage points: injection site reactions (25.1% vs. 6.2%), arthralgia (13.3% vs. 7.3%), and peripheral edema (10.5% vs. 3.9%). [2] These events are GH-mediated and would be expected to occur at higher frequency in children given the amplified GH response predicted by pituitary physiology in this age group.

Sodium and Water Retention

GH promotes renal sodium reabsorption. In adult trials, tesamorelin produced clinically meaningful peripheral edema in approximately 1 in 10 patients. [2] Children with cardiac conditions, nephrotic syndrome, or those already on medications that promote fluid retention would face amplified risk. A 2019 review in JAMA Pediatrics noted that GH-secretagogue-related fluid retention has not been systematically studied in children younger than 8 years old, representing a genuine evidence gap. [19]

Neoplasm Risk and the IGF-1 Question

The FDA label for tesamorelin carries a warning that the drug is not indicated for patients with active malignancy. [1] This warning has particular weight in children, given that pediatric cancers (leukemia, brain tumors, sarcomas) sometimes present with nonspecific symptoms that could be masked or worsened by IGF-1 elevation. A 2021 systematic review in JAMA Oncology found that higher circulating IGF-1 at diagnosis correlated with worse outcomes in pediatric osteosarcoma. [20] Any child with an undiagnosed mass or unexplained cytopenias should be fully evaluated before any GH-axis stimulation is considered.

Glucose Dysregulation in Young Children

Children under 12 on antiretroviral therapy already have elevated rates of insulin resistance. A 2017 cohort study published in Pediatric Infectious Disease Journal (N=203) found that 28% of HIV-positive children aged 5 to 11 met criteria for prediabetes by fasting glucose criteria. [21] Adding tesamorelin-induced GH counter-regulation to this background rate could push a meaningful fraction of these children toward overt type 2 diabetes. Clinicians must weigh this risk explicitly.

What Pediatric Endocrinology Guidelines Say

The Endocrine Society's 2016 Clinical Practice Guideline on Growth Hormone Deficiency in Children states that "diagnosis and treatment of GH deficiency in children should be performed by or in consultation with a pediatric endocrinologist." [3] That guideline does not address tesamorelin because the drug had no pediatric data at the time of publication and remains without pediatric data today.

The Pediatric Endocrine Society has not issued a position statement on tesamorelin in children under 12. In the absence of society guidance, clinicians should treat this scenario as they would any high-uncertainty off-label pediatric intervention and default to the ethical principles outlined in the AAP's 2014 policy statement on off-label drug use. [18]

A direct quotation from the FDA-approved Egrifta prescribing information is instructive: "The safety and effectiveness of EGRIFTA have not been established in pediatric patients." [1] This language, unlike a relative contraindication, represents a complete absence of evidence rather than a finding of harm, but the practical clinical implication is the same: the prescriber carries the full evidentiary burden.

The Endocrine Society's position on GHRH analogs and the GH axis notes that "use of GHRH analogs outside their approved indications requires careful consideration of the physiologic differences between the target population and the populations in which evidence was generated." [22] This principle applies with particular force to children under 12, whose GH axis physiology differs substantially from HIV-positive adults.

Practical Considerations for the Clinician Receiving a Pediatric Tesamorelin Request

Clinicians at telehealth platforms or outpatient endocrinology practices may occasionally receive requests from parents who have read about tesamorelin for lipodystrophy or GH augmentation in their child under 12. A structured response includes the following steps.

Confirming the Diagnosis

Lipodystrophy diagnosis in children requires dual-energy X-ray absorptiometry (DEXA) to document regional fat distribution, fasting lipid panel, fasting insulin, and genetic testing if familial partial lipodystrophy is suspected. Misidentifying normal childhood adipose distribution as lipodystrophy is a documented clinical error. [23] The diagnosis must be confirmed before any pharmacologic intervention is considered.

Documented Treatment Sequence

First-line treatment for HIV-associated lipodystrophy in children remains ART regimen optimization, specifically switching away from thymidine analogs (stavudine, zidovudine) and protease inhibitors where virologically feasible. [13] A 2020 open-label study (N=34 children, mean age 9.3 years) published in Pediatric Infectious Disease Journal showed that switching from a stavudine-based to an abacavir-based regimen produced significant limb fat recovery at 48 weeks without any GH-axis intervention. [24]

When to Refer

Any child under 12 where the clinical team is genuinely considering tesamorelin should be referred to a pediatric endocrinologist at a center with active research protocols. UCSF, Boston Children's, and Cincinnati Children's each maintain lipodystrophy registries that may offer clinical trial access. Participation in a registry or trial provides the patient access to the intervention under monitored conditions and contributes to the evidence base the field urgently needs. [25]